10-Q: Quarterly report pursuant to Section 13 or 15(d)
Published on November 7, 2023
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
________________________
FORM 10-Q
________________________
(Mark One)
For the quarterly period ended September 30, 2023
or
For the transition period from __________ to __________
Commission File Number
001-40860
________________________
(Exact name of registrant as specified in its charter)
________________________
|
|
|||||||
(State
or other jurisdiction of
incorporation
or organization)
|
(I.R.S.
Employer
Identification
No.)
|
Address
not applicable1
(Address of principal executive offices and zip code)
(
310 ) 691-0776
(Registrant’s telephone number, including area code)
________________________
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
||||||||||||
|
|
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or
for such shorter period that the registrant was required to submit such files).
Yes
☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,
a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
☒ | Accelerated Filer | ☐ | ||||||||
Non-accelerated Filer | ☐ | Smaller reporting company |
|
||||||||
Emerging growth company |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange
Act). Yes ☐ No
☒
As
of November 3, 2023, registrant had 654,733,052
shares of common stock, par value $0.001 per share, outstanding.
1
Olaplex Holdings, Inc. is a fully remote company. Accordingly, it does not maintain a principal executive
office.
OLAPLEX HOLDINGS, INC.
TABLE OF CONTENTS
Page | ||||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
1
GLOSSARY
As
used in this Quarterly Report on Form 10-Q (“Quarterly Report”), the terms identified below have the meanings
specified below unless otherwise noted or the context indicates otherwise. Except where the context otherwise
requires or where otherwise indicated, the terms “OLAPLEX”
“we,” “us,” “our,” “the Company,” and “our business” refer to Olaplex
Holdings, Inc.
and its consolidated subsidiaries.
•“2020
Credit Agreement”
refers to the Credit Agreement, dated as of January 8, 2020, by and among Olaplex, Inc., Penelope Intermediate
Corp., MidCap Financial Trust, as administrative agent, collateral agent and swingline lender, and each lender and
issuing bank from time to time party thereto, as amended by the First Incremental Amendment to the 2020 Credit
Agreement, dated as of December 18, 2020. The 2020 Credit Agreement was refinanced and replaced by the 2022 Credit
Agreement.
•“2022
Credit Agreement”
refers to the Credit Agreement, dated as of February 23, 2022, by and among Olaplex, Inc., Penelope Intermediate
Corp, Goldman Sachs Bank USA, as administrative agent, collateral agent and swingline lender, and each lender and
issuing bank from time to time party thereto. The 2022 Credit Agreement refinanced and replaced the 2020 Credit
Agreement, and includes, among other things, a $675 million seven-year senior-secured term loan facility (the
“2022 Term Loan Facility”) and a $150 million five-year senior-secured revolving credit facility (the “2022
Revolver”).
•“IPO”
refers to the initial public offering of shares of common stock of Olaplex Holdings, Inc., completed on October 4,
2021.
•“Penelope”
refers to Penelope Holdings Corp., which is an indirect parent of Olaplex, Inc., the Company’s primary operating
subsidiary.
•“Penelope
Group Holdings”
refers to Penelope Group Holdings L.P., which prior to the IPO was the direct parent of Penelope.
•“Pre-IPO
Stockholders”
refers to, collectively, (i) the former limited partners of Penelope Group Holdings prior to the Reorganization
Transactions and (ii) holders of options to purchase shares of common stock of Penelope that were vested as of the
consummation of the Reorganization Transactions.
•“Pre-IPO
Tax Assets”
refers to, collectively, certain tax attributes existing prior to the IPO, including tax basis in intangible
assets and capitalized transaction costs relating to taxable years ending on or before the date of the IPO
(calculated by assuming the taxable year of the relevant entity closes on the date of the IPO), that are
amortizable over a fixed period of time (including in tax periods beginning after the IPO) and which are available
to us and our wholly-owned subsidiaries.
•“Reorganization
Transactions”
refers to the internal reorganization completed in connection with our IPO, pursuant to which Olaplex Holdings,
Inc. became an indirect parent of Olaplex, Inc. For further information, see “Reorganization Transactions” in
“Note 1 - Nature of Operations and Basis of Presentation” to our Consolidated Financial Statements included in
Part II, Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2022.
•“Tax
Receivable Agreement”
refers to the income tax receivable agreement entered into by the Company in connection with the Reorganization
Transactions under which the Company is required to pay the Pre-IPO Stockholders 85% of the cash savings, if any,
in United States (“U.S.”) federal, state or local tax that the Company actually realizes on its taxable income
following the IPO, as specified in the Tax Receivable Agreement.
2
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report on Form 10-Q (the “Quarterly Report”) contains certain forward-looking statements and information
relating to us that are based on the beliefs of our management as well as assumptions made by, and information
currently available to, us. These statements include, but are not limited to, statements about our strategies,
plans, objectives, expectations, intentions, expenditures and assumptions and other statements contained in or
incorporated by reference in this Quarterly Report that are not historical or current facts. When used in this
document, words such as “may,” “will,” “could,” “should,” “intend,” “potential,” “continue,” “anticipate,”
“believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “forecast,” “seek” and similar
expressions as they relate to us are intended to identify forward-looking statements.
The
forward-looking statements in this Quarterly Report reflect our current expectations and projections about future
events and financial trends that we believe may affect our business, financial condition and results of operation.
Examples of forward-looking statements include, among others, statements we make regarding: our financial position
and operating results; our business plans, strategies and objectives, including sales and marketing investments;
general economic and industry trends; our business prospects; our reputation and brand; our product technology;
future product development and introduction, including entry into adjacent and other categories; growth and
expansion opportunities, including expansion in existing markets and into new markets; our sales channels and
omnichannel strategy; legal proceedings; future payments under our Tax Receivable Agreement; our customer base;
our supply chain and global distribution network; our information technology; our employees and culture; our
operational capabilities; interest rate derivatives; and our expenses, inventory levels, other working capital and
liquidity. Forward-looking statements are predictions based upon assumptions that may not prove to be accurate,
and they are not guarantees of future performance. As such, you should not place significant reliance on our
forward-looking statements. Neither we nor any other person assumes responsibility for the accuracy and
completeness of the forward-looking statements, including any such statements taken from third party industry and
market reports.
Forward-looking
statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to predict
which may cause our actual results, performance, time frames or achievements to be materially different from any
future results, performance, time frames or achievements expressed or implied by the forward-looking statements,
including, without limitation, the following:
•our
ability to anticipate and respond to market trends and changes in consumer preferences and execute on our growth
strategies and expansion opportunities, including with respect to new product introductions;
•our
ability to develop, manufacture and effectively and profitably market and sell future products;
•our
ability to accurately forecast customer and consumer demand for our products;
•competition
in the beauty industry;
•our
ability to effectively maintain and promote a positive brand image and expand our brand awareness;
•our
dependence on a limited number of customers for a large portion of our net sales;
•our
ability to attract new customers and consumers and encourage consumer spending across our product
portfolio;
•our
ability to successfully implement new or additional marketing efforts;
•our
relationships with and the performance of our suppliers, manufacturers, distributors and retailers and our ability
to manage our supply chain;
•impacts
on our business from political, regulatory, economic, trade and other risks associated with operating
internationally;
•our
ability to manage our executive leadership change and to attract and retain senior management and other qualified
personnel;
•our
reliance on our and our third-party service providers’ information technology;
•our
ability to maintain the security of confidential information;
•our
ability to establish and maintain intellectual property protection for our products, as well as our ability to
operate our business without infringing, misappropriating or otherwise violating the intellectual property rights
of others;
•the
outcome of litigation and regulatory proceedings;
•the
impact of changes in federal, state and international laws, regulations and administrative policy;
3
•our
existing and any future indebtedness, including our ability to comply with affirmative and negative covenants
under the 2022 Credit Agreement;
•our
ability to service our existing indebtedness and obtain additional capital to finance operations and our growth
opportunities;
•volatility
of our stock price;
•our
“controlled company” status and the influence of investment funds affiliated with Advent International L.P. over
us;
•the
impact of an economic downturn and inflationary pressures on our business;
•fluctuations
in our quarterly results of operations;
•changes
in our tax rates and our exposure to tax liability; and
•the
other factors identified in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended
December 31, 2022 (the “2022 Form 10-K”) and in other documents that we file with the U.S. Securities and Exchange
Commission from time to time.
Many
of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results,
performance or achievements may vary materially from those described in this Quarterly Report as anticipated,
believed, estimated, expected, intended, planned or projected. We discuss many of these risks in greater detail in
the “Risk Factors” section of our 2022 Form 10-K. The forward-looking statements included in this Quarterly Report
are made only as of the date hereof. Unless required by law, we neither intend nor assume any obligation to update
these forward-looking statements for any reason after the date of this Quarterly Report to conform these
statements to actual results or to changes in our expectations or otherwise.
4
PART
I - FINANCIAL INFORMATION
ITEM 1. Financial Statements
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts
in thousands, except per share and share data)
(Unaudited)
September
30, 2023 |
December
31, 2022 |
||||||||||
Assets | |||||||||||
Current Assets: | |||||||||||
Cash and cash equivalents | $ |
|
$ |
|
|||||||
Accounts
receivable, net of allowances of $
|
|
|
|||||||||
Inventory |
|
|
|||||||||
Other current assets |
|
|
|||||||||
Total current assets |
|
|
|||||||||
Property and equipment, net |
|
|
|||||||||
Intangible assets, net |
|
|
|||||||||
Goodwill |
|
|
|||||||||
Other assets |
|
|
|||||||||
Total assets | $ |
|
$ |
|
|||||||
Liabilities and stockholders’ equity | |||||||||||
Current Liabilities: | |||||||||||
Accounts payable | $ |
|
$ |
|
|||||||
Sales and income taxes payable, net |
|
|
|||||||||
Accrued expenses and other current liabilities |
|
|
|||||||||
Current portion of long-term debt |
|
|
|||||||||
Current portion of Related Party payable pursuant to Tax Receivable Agreement |
|
|
|||||||||
Total current liabilities |
|
|
|||||||||
Long-term debt |
|
|
|||||||||
Deferred tax liabilities |
|
|
|||||||||
Related Party payable pursuant to Tax Receivable Agreement |
|
|
|||||||||
Other liabilities |
|
|
|||||||||
Total liabilities |
|
|
|||||||||
Contingencies
(Note 10)
|
|
|
|||||||||
Stockholders’
equity (Notes 1 and 8):
|
|||||||||||
Common
stock, $
|
|
|
|||||||||
Preferred
stock, $
|
|
|
|||||||||
Additional
paid-in capital
|
|
|
|||||||||
Accumulated other comprehensive income |
|
|
|||||||||
Retained
earnings
|
|
|
|||||||||
Total stockholders’ equity |
|
|
|||||||||
Total liabilities and stockholders’ equity | $ |
|
$ |
|
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
5
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(amounts
in thousands, except per share and share data)
(Unaudited)
Three
Months Ended September 30, |
Nine
Months Ended September 30, |
||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Net sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Cost of sales: | |||||||||||||||||||||||
Cost of product (excluding amortization) |
|
|
|
|
|||||||||||||||||||
Amortization of patented formulations |
|
|
|
|
|||||||||||||||||||
Total cost of sales |
|
|
|
|
|||||||||||||||||||
Gross profit |
|
|
|
|
|||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Selling, general, and administrative |
|
|
|
|
|||||||||||||||||||
Amortization of other intangible assets |
|
|
|
|
|||||||||||||||||||
Total operating expenses |
|
|
|
|
|||||||||||||||||||
Operating income |
|
|
|
|
|||||||||||||||||||
Interest expense, net |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Other expense, net | |||||||||||||||||||||||
Loss on extinguishment of debt |
|
|
|
(
|
|||||||||||||||||||
Other expense, net |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Total other expense, net |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Income
before provision for income taxes
|
|
|
|
|
|||||||||||||||||||
Income tax provision |
|
|
|
|
|||||||||||||||||||
Net income | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Net income per share: | |||||||||||||||||||||||
Basic | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Diluted | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||||
Basic |
|
|
|
|
|||||||||||||||||||
Diluted |
|
|
|
|
|||||||||||||||||||
Other comprehensive (loss) income: | |||||||||||||||||||||||
Unrealized (loss) gain on derivatives, net of income tax effect | $ | (
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Total other comprehensive (loss) income: |
(
|
|
|
|
|||||||||||||||||||
Comprehensive income: | $ |
|
$ |
|
$ |
|
$ |
|
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
6
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(amounts
in thousands, except number of shares)
(Unaudited)
Shares (Note 1) |
Amount | Additional
Paid in Capital |
Accumulated Other Comprehensive Income | Retained
Earnings |
Total Equity | ||||||||||||||||||||||||||||||
Balance - December 31, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Exercise of stock-settled stock appreciation rights |
|
— |
|
— | — |
|
|||||||||||||||||||||||||||||
Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights |
(
|
— |
(
|
— | — |
(
|
|||||||||||||||||||||||||||||
Exercise of stock options |
|
|
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Unrealized loss on derivatives (net of taxes) | — | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
Balance – March 31, 2023 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Exercise of stock options |
|
|
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Unrealized gain on derivatives (net of taxes) | — | — | — |
|
— |
|
|||||||||||||||||||||||||||||
Balance – June 30, 2023 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Exercise of stock options |
|
— |
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Unrealized loss on derivatives (net of taxes) | — | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
Balance
– September 30, 2023
|
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
Shares (Note 1) |
Amount | Additional
Paid in Capital |
Accumulated Other Comprehensive Income |
Retained Earnings |
Total Equity | ||||||||||||||||||||||||||||||
Balance - December 31, 2021 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Conversion of cash settled units to stock appreciation rights | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Exercise of stock-settled stock appreciation rights |
|
— |
|
— | — |
|
|||||||||||||||||||||||||||||
Shares withheld and retired for taxes on exercise of stock-settled stock appreciation rights |
(
|
— |
(
|
— | — |
(
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Balance – March 31, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — |
|
|
||||||||||||||||||||||||||||||
Exercise of stock options |
|
|
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— |
|
||||||||||||||||||||||||||||||
Balance – June 30, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
Net income | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
Exercise of stock options |
|
— |
|
— | — |
|
|||||||||||||||||||||||||||||
Share-based compensation expense | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
Unrealized gain on derivatives (net of taxes) | — | — | — |
|
— |
|
|||||||||||||||||||||||||||||
Balance
– September 30, 2022
|
|
PY | $ |
|
PY | $ |
|
$ |
|
$ |
|
$ |
|
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
7
OLAPLEX HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts
in thousands)
(Unaudited)
Nine
Months Ended September 30, |
|||||||||||
2023 | 2022 | ||||||||||
Cash
flows from operating activities:
|
|||||||||||
Net income | $ |
|
$ |
|
|||||||
Adjustments to reconcile net income to net cash from operations provided by operating activities: | |||||||||||
Amortization
of patent formulations
|
|
|
|||||||||
Amortization
of other intangibles
|
|
|
|||||||||
Inventory
write-off and disposal
|
|
|
|||||||||
Depreciation
of fixed assets
|
|
|
|||||||||
Amortization
of debt issuance costs
|
|
|
|||||||||
Deferred
taxes
|
|
(
|
|||||||||
Share-based
compensation expense
|
|
|
|||||||||
Loss
on extinguishment of debt
|
|
|
|||||||||
Other operating |
|
|
|||||||||
Changes in operating assets and liabilities, net of effects of acquisition (as applicable): | |||||||||||
Accounts
receivable, net
|
(
|
(
|
|||||||||
Inventory
|
|
(
|
|||||||||
Other
current assets
|
|
|
|||||||||
Accounts
payable
|
|
|
|||||||||
Accrued
expenses and other current liabilities
|
(
|
|
|||||||||
Other assets and liabilities |
(
|
(
|
|||||||||
Net cash provided by operating activities |
|
|
|||||||||
Cash flows from investing activities: | |||||||||||
Purchase
of property and equipment
|
(
|
(
|
|||||||||
Purchase of intangible assets |
(
|
|
|||||||||
Purchase
of software
|
(
|
(
|
|||||||||
Net cash used in investing activities |
(
|
(
|
|||||||||
Cash flows from financing activities: | |||||||||||
Proceeds
from exercise of stock options
|
|
|
|||||||||
Payments
for shares withheld and retired for taxes and exercise price for stock-settled share appreciation
rights
|
(
|
(
|
|||||||||
Payment to pre-IPO stockholders pursuant to Tax Receivable Agreement |
(
|
|
|||||||||
Principal
payments for 2022 Term Loan Facility, and principal payments and prepayment fees for 2020 Term Loan
Facility
|
(
|
(
|
|||||||||
Proceeds
from the issuance of 2022 Term Loan Facility
|
|
|
|||||||||
Payments
of debt issuance costs
|
|
(
|
|||||||||
Net cash used in financing activities |
(
|
(
|
|||||||||
Net increase in cash and cash equivalents |
|
|
|||||||||
Cash and cash equivalents - beginning of period |
|
|
|||||||||
Cash and cash equivalents - end of period | $ |
|
$ |
|
|||||||
Supplemental disclosure of cash flow information: | |||||||||||
Cash
paid for income taxes
|
$ |
|
$ |
|
|||||||
Cash
paid during the year for interest
|
$ |
|
$ |
|
|||||||
Supplemental disclosure of noncash activities: | |||||||||||
Cash-settled
units liability reclassification to additional paid in capital
|
$ |
|
$ |
|
|||||||
Assets acquired under operating lease | $ |
|
$ |
|
The
accompanying notes are an integral part of these Condensed Consolidated Financial Statements
8
OLAPLEX HOLDINGS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in
thousands, except share and per share amounts, percentages and as otherwise indicated)
(Unaudited)
NOTE 1- NATURE OF OPERATIONS AND BASIS OF PRESENTATION
Olaplex
Holdings, Inc. (“Olaplex Holdings” and, together with its subsidiaries, the “Company”) is a Delaware corporation
that was incorporated on June 8, 2021. Olaplex Holdings is organized as a holding company and operates
indirectly through its wholly owned subsidiaries, Penelope and Olaplex, Inc., which conducts business under the
name “Olaplex”. Olaplex is an innovative, science-enabled, technology-driven beauty company that is focused on
delivering its patent-protected prestige hair care products to professional hair salons, retailers and everyday
consumers. Olaplex develops, manufactures and distributes a line of hair care products developed to address
three key uses: treatment, maintenance and protection.
Basis of Presentation
The
accompanying unaudited interim Condensed Consolidated Financial Statements have been prepared in accordance
with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with
the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange
Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by U.S.
GAAP for complete financial statements. The unaudited interim Condensed Consolidated Financial Statements
furnished reflect all adjustments which are, in the opinion of management, necessary for a fair statement of
the results for the interim periods presented. The results of operations of any interim period are not
necessarily indicative of the results of operations to be expected for the full fiscal year. The unaudited
interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated
Financial Statements and accompanying footnotes included in the Company’s 2022 Form 10-K.
NOTE 2 – SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES
Estimates and Assumptions
Preparing
financial statements requires management to make estimates and assumptions that affect the reported amounts of
assets, liabilities, revenue, and expenses. Examples of estimates and assumptions include: for revenue
recognition, determining the nature and timing of satisfaction of performance obligations, variable
consideration, and other obligations such as product returns, allowance for promotions, and refunds; loss
contingencies; the fair value of share-based options and stock settled stock appreciation rights (“SARs”); the
fair value of and/or potential impairment of goodwill and intangible assets for the Company’s reporting unit;
the fair value of the Company’s interest rate cap; useful lives of the Company’s tangible and intangible
assets; estimated income tax and tax receivable payments; the net realizable value of, and demand for the
Company’s inventory. Actual results and outcomes may differ from management’s estimates and assumptions due to
risks and uncertainties.
Fair Value of Financial Instruments
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement date. The authoritative guidance for fair
value measurements established a framework for measuring fair value and established a three-level valuation
hierarchy for disclosure of fair value measurements as follows:
Level 1—Observable
inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. The
Company’s Level 1 assets consist of its marketable securities.
Level 2—Observable
quoted prices for similar assets or liabilities in active markets and observable quoted prices for identical
assets or liabilities in markets that are not active.
Level 3—Unobservable
inputs that are not corroborated by market data.
Cash
and cash equivalents, accounts receivable, accounts payable and accrued expenses are reflected at carrying
value, which approximates fair value due to the short-term maturity. The Company’s long-term debt is recorded
at its carrying value in the Condensed Consolidated Balance Sheets, which may differ from fair value. The
Company’s interest rate cap is recorded at its Level 3 fair value in the Condensed Consolidated Balance
Sheets.
9
Accounting Policies
There
have been no material changes in significant accounting policies as described in the Company’s Consolidated
Financial Statements for the year ended December 31, 2022.
Constructive Retirement of Common Stock Repurchases
When
the Company's common stock is retired or purchased for constructive retirement for net share settlement of
stock options, any excess purchase price over par value is allocated between additional paid-in-capital, to
the extent that previous net gains from sales or retirements are included therein, and the remainder to
retained earnings.
Tax Receivable Agreement
As
part of the IPO, the Company entered into the Tax Receivable Agreement under which the Company will be
required to pay to the Pre-IPO Stockholders 85% of the federal, state or local tax cash savings that the
Company actually realizes on its taxable income following the IPO, as a result of the amortization of
intangible assets and capitalized transaction costs that existed as of the date of the IPO. Under the Tax
Receivable Agreement, generally the Company will retain the benefit of the remaining 15% of the applicable tax
savings.
The
Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that the Company
and its subsidiaries will earn sufficient taxable income to realize the full tax benefits subject to the Tax
Receivable Agreement. Updates to the Company’s blended state tax rate and allocation of U.S. versus foreign
sourced income may impact the established liability and changes to that established liability would be
recorded to other income (expense) in the period the Company made the determination regarding the applicable
change. The Company expects that future payments under the Tax Receivable Agreement relating to the Pre-IPO
Tax Assets could aggregate to $205.6
million
over
the 13-year remaining period under the Tax Receivable Agreement. Payments under the Tax Receivable Agreement,
which began in the year ended December 31, 2022, are not conditioned upon the parties’ continued ownership of
equity in the Company.
Reclassifications
Certain
amounts presented have been reclassified within “Note 6 - Accrued Expenses and Other Current Liabilities” as
of December
31, 2022
to conform with the current period presentation, including a prior year reclassification from Other accrued
expenses and current liabilities to Accrued advertising and Accrued inventory purchases. The reclassifications
had no effect on the Company’s Total current liabilities.
NOTE 3 – NET SALES
The
Company distributes products in the U.S. and internationally through professional distributors in the salon
channel, directly to retailers for sale in their physical stores and e-commerce sites, and direct-to-consumer
(“DTC”) through sales to third-party e-commerce customers and through its own Olaplex.com website.
As such, the Company’s three business channels consist of professional, specialty retail and DTC as
follows:
For
the Three Months Ended
|
For
the Nine Months Ended
|
||||||||||||||||||||||
September 30, 2023 | September 30, 2022 | September 30, 2023 | September 30, 2022 | ||||||||||||||||||||
Net sales by Channel: | |||||||||||||||||||||||
Professional | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Specialty retail |
|
|
|
|
|||||||||||||||||||
DTC |
|
|
|
|
|||||||||||||||||||
Total net sales | $ |
|
$ |
|
$ |
|
$ |
|
10
Revenue
by major geographic region is based upon the geographic location of customers who purchase the Company’s
products. The majority of net sales are transacted in U.S. Dollars, the Company’s functional and reporting
currency. During the three and nine months ended
September 30, 2023 and September 30, 2022, the Company’s net sales to consumers in the United States
and International regions were as follows:
For
the Three Months Ended
|
For
the Nine Months Ended
|
||||||||||||||||||||||
September 30, 2023 | September 30, 2022 | September 30, 2023 | September 30, 2022 | ||||||||||||||||||||
Net sales by Geography: | |||||||||||||||||||||||
United States | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
International |
|
|
|
|
|||||||||||||||||||
Total net sales | $ |
|
$ |
|
$ |
|
$ |
|
United
Kingdom (“U.K.”) net sales for the three and nine months ended September 30, 2023 were 7 % and 8 % of total net sales,
respectively, and for the three and nine months ended September 30, 2022 were 13 % and 10 % of total net sales,
respectively. No other international country exceeded 10% of total net sales for the three and nine months ended
September 30, 2023 and September 30, 2022.
NOTE 4 - INVENTORY
Inventory
as of September 30, 2023 and December 31, 2022 consisted of the following:
September 30, 2023 | December 31, 2022 | ||||||||||
Raw materials and packaging components | $ |
|
$ |
|
|||||||
Finished goods |
|
|
|||||||||
Inventory | $ |
|
$ |
|
During
the three and nine months ended September 30, 2023, the Company recorded inventory write-offs of $
3.6 million and $9.8 million, respectively, due to reserves for product
obsolescence. The Company did
not
record material write-offs for product obsolescence during the same periods ended
September 30, 2022.
NOTE 5 –
GOODWILL AND INTANGIBLE ASSETS
Goodwill
and intangible assets are comprised of the following:
September 30, 2023 | |||||||||||||||||||||||
Estimated Useful Life |
Gross
Carrying Amount |
Accumulated
Amortization |
Net
Carrying
Amount
|
||||||||||||||||||||
Brand name |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||
Product formulations |
|
|
(
|
|
|||||||||||||||||||
Customer relationships |
|
|
(
|
|
|||||||||||||||||||
Software |
|
|
(
|
|
|||||||||||||||||||
Total
finite-lived intangibles
|
|
(
|
|
||||||||||||||||||||
Goodwill | Indefinite |
|
— |
|
|||||||||||||||||||
Total
goodwill and other intangibles
|
$ |
|
$ |
(
|
$ |
|
11
December 31, 2022 | |||||||||||||||||||||||
Estimated Useful Life |
Gross Carrying Amount |
Accumulated
Amortization |
Net
Carrying
Amount
|
||||||||||||||||||||
Brand name |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||
Product formulations |
|
|
(
|
|
|||||||||||||||||||
Customer relationships |
|
|
(
|
|
|||||||||||||||||||
Software |
|
|
(
|
|
|||||||||||||||||||
Total
finite-lived intangibles
|
|
(
|
|
||||||||||||||||||||
Goodwill | Indefinite |
|
— |
|
|||||||||||||||||||
Total
goodwill and other intangibles
|
$ |
|
$ |
(
|
$ |
|
The
amortization of the Company’s brand name, customer relationships and software is recorded to Amortization of
other intangible assets in the Condensed Consolidated Statements of Operations and Comprehensive Income. A
portion of Amortization of patented formulations is capitalized to Inventory in the Condensed Consolidated
Balance Sheets, and the remainder is recorded to Amortization of patented formulations in the Condensed
Consolidated Statements of Operations and Comprehensive Income. Amortization of the Company’s definite-lived intangible assets for the three and nine months
ended September 30, 2023 and 2022 was as follows:
For
the Three Months Ended
|
For
the Nine Months Ended
|
||||||||||||||||||||||
September 30, 2023 | September 30, 2022 | September 30, 2023 | September 30, 2022 | ||||||||||||||||||||
Amortization of patented formulations | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Amortization expense, brand name and customer relationships |
|
|
|
|
|||||||||||||||||||
Amortization expense, software |
|
|
|
|
|||||||||||||||||||
Amortization of other intangible assets |
|
|
|
|
|||||||||||||||||||
Amortization of patented formulations capitalized to inventory | $ | (
|
$ |
|
$ |
|
$ |
|
NOTE 6 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued
expenses as of September 30, 2023 and December 31, 2022 consisted of the following:
September 30, 2023 | December 31, 2022 | ||||||||||
Accrued professional fees | $ |
|
$ |
|
|||||||
Payroll liabilities |
|
|
|||||||||
Accrued freight |
|
|
|||||||||
Accrued inventory purchases |
|
|
|||||||||
Accrued advertising |
|
|
|||||||||
Deferred revenue |
|
|
|||||||||
Other accrued expenses and current liabilities |
|
|
|||||||||
Accrued interest |
|
|
|||||||||
Accrued expenses and other current liabilities | $ |
|
$ |
|
12
NOTE 7 - LONG-TERM DEBT
The
Company’s Long-Term Debt as of September 30, 2023 and December 31, 2022 consisted of the
following:
September 30, 2023 | December 31, 2022 | ||||||||||
Long-term debt | |||||||||||
Credit Agreement, dated as of February 23, 2022 (the “2022 Credit Agreement”) | |||||||||||
$
|
$ |
|
$ |
|
|||||||
$
|
|
|
|||||||||
Debt issuance costs | (
|
(
|
|||||||||
Total
term loan debt
|
|
|
|||||||||
Less: Current portion | (
|
(
|
|||||||||
Long-term
debt, net of debt issuance costs and current portion
|
$ |
|
$ |
|
(1)
As
of September 30, 2023 and December 31, 2022, the Company did not have outstanding amounts drawn on
the 2022 Revolver, including letters of credit and swingline loan sub-facilities. As of September 30,
2023, the Company had $150 million of available borrowing capacity under the 2022 Revolver.
The
interest rate on outstanding debt under the 2022 Term Loan Facility was 8.9 % per annum as of September 30, 2023. The interest rates for all
facilities under the 2022 Credit Agreement are calculated based upon the Company’s election among (a) adjusted
term SOFR plus an additional interest rate spread, (b) with respect to a borrowing in Euros under the 2022
Revolver, a euro interbank offered rate plus an additional interest rate spread, or (c) an “Alternate Base Rate”
(as defined in the 2022 Credit Agreement) plus an additional interest rate spread.
Interest
expense, net, inclusive of debt amortization, for the three months ended September 30, 2023 and
September 30, 2022 was $9.5
million and $10.5 million respectively, and for the nine
months ended September 30, 2023 and September 30, 2022 was $30.3 million and $30.7
million, respectively.
The
fair value of the Company’s long-term debt is based on the market value of its long-term debt instrument. Based
on the inputs used to value the long-term debt, the Company’s long-term debt is categorized within Level 2 in
the fair value hierarchy. As of September 30, 2023, the carrying amount of the Company’s long-term debt
under the 2022 Credit Agreement was $657.1 million,
and the fair value of the Company’s long-term debt was $555.2
million. As of December 31, 2022, the carrying amount of the Company’s long-term debt
under the 2022 Credit Agreement was $662.8
million, and the fair value of the Company’s long-term debt was $624.6 million.
The
2022 Credit Agreement includes, among other things, customary negative and affirmative covenants (including
reporting, financial and maintenance covenants) and events of default (including a change of control) for
facilities of this type. In addition, the 2022 Credit Agreement includes a springing first lien leverage ratio
financial covenant, which is applicable only to the lenders under the 2022 Revolver. The Company was in
compliance with its financial covenants on September 30, 2023 and December 31, 2022. The 2022 Term
Loan Facility and the 2022 Revolver are secured by substantially all of the assets of Olaplex, Inc. and the
other guarantors, subject to certain exceptions and thresholds.
Interest Rate Cap Transaction
The
Company’s results are subject to risk from interest rate fluctuations on borrowings under the 2022 Credit
Agreement, including the 2022 Term Loan Facility. The Company may, from time to time, utilize interest rate
derivatives in an effort to add stability to interest expense and to manage its exposure to interest rate
movements. On August 11, 2022, the Company entered into an interest rate cap transaction (the “interest
rate cap”) in connection with the 2022 Term Loan Facility, with a notional amount of $400 million. Interest rate caps
designated as cash flow hedges involve the receipt of variable amounts from a counterparty if interest rates
rise above the strike rate applicable to the transaction, in exchange for an up-front premium paid by the
Company. The Company has designated the interest rate cap as a cash-flow hedge for accounting purposes.
For
derivatives designated, and that qualify, as cash flow hedges of interest rate risk, the gain or loss on the
derivative is recorded in Accumulated other comprehensive income and subsequently reclassified into Interest
expense, net in the same period(s) during which the hedged transaction affects earnings, as documented at hedge
inception in accordance with the Company’s accounting policy election.
13
The
table below presents the fair value of the Company’s derivative financial instruments, which are classified
within Other assets on the Company’s Condensed Consolidated Balance Sheets as of September 30, 2023 and
December 31, 2022.
September 30, 2023 | December 31, 2022 | ||||||||||
Fair value, interest rate cap asset | $ |
|
$ |
|
During
the three and nine months ended September 30, 2023, the Company’s interest rate cap generated an
unrecognized pre-tax loss of $0.7
million and a gain of $0.3
million, respectively, recorded in Accumulated other comprehensive income on the
Company’s Condensed Consolidated Balance Sheets. During the same periods, the Company also recognized a $
1.3 million and $
2.8 million reduction, respectively, in interest expense related to the Company’s
receipt of funds as a result of an interest rate cap settlement with the Company’s counterparty, partially
offset by $0.3 million and $0.8 million, respectively, of interest expense related to
amortization of the interest rate cap premium paid by the Company in connection with the interest rate cap.
During
each of the three and nine months ended September 30, 2022, the Company’s interest rate cap generated an
unrecognized pre-tax gain of $
2.4
million, recorded in Accumulated other comprehensive income on the Company’s Condensed
Consolidated Balance Sheets. During the same periods, the Company also recognized $
0.1
million of interest expense related to amortization of the interest rate cap premium paid
by the Company in connection with the interest rate cap.
The
Company performed an initial effectiveness assessment on the interest rate cap and determined it to be an
effective hedge of the cash flows related to the interest rate payments on the 2022 Term Loan Facility. The
hedge is evaluated qualitatively on a quarterly basis for effectiveness. Changes in fair value are recorded in
Accumulated other comprehensive income and periodic settlements of the interest rate cap will be recorded in
Interest expense, net along with the interest on amounts outstanding under the 2022 Term Loan Facility. Payment
of the up-front premium of the interest rate cap is included within Other assets and liabilities within cash
flows from operating activities on the Company’s Condensed Consolidated Statements of Cash Flows.
The
Company does not hold or issue derivative financial instruments for trading purposes, nor does it hold or issue
leveraged derivative instruments. By using derivative financial instruments to hedge exposures to interest rate
fluctuations, the Company exposes itself to counterparty credit risk. The Company manages exposure to
counterparty credit risk by entering into derivative financial instruments with highly rated institutions that
can be expected to fully perform under the terms of the applicable contracts.
NOTE 8 - EQUITY
During
the nine months ended September 30, 2023, the Company issued 109,620 shares of its common stock upon
vesting and settlement of net stock-settled SARs. The Company repurchased 83,501 of outstanding shares of its common
stock for the net settlement of SARs for payment of taxes related to such SARs, which were accounted for as a
share retirement.
Additionally,
during the nine months ended September 30, 2023, the Company issued 4,606,867 shares of its common stock as a
result of stock options exercised.
On
August 2, 2023, the Company adopted the Amended and Restated 2020 Omnibus Equity Incentive Plan, effective
September 27, 2021, which amended and restated the Penelope Holdings Corp. 2020 Omnibus Equity Incentive Plan
(the "Original Plan") solely to reflect the Reorganization Transactions and the assumption by the Company of the
Original Plan.
During
the nine months ended September 30, 2022, the Company converted 886,950 cash-settled units into SARs, with
a fair value liability of $1,632 reclassified from Accrued expenses
and other current liabilities to Additional paid-in capital. The Company issued 117,180 shares of its common stock upon
vesting and settlement of net stock-settled SARs. The Company repurchased 55,244 of outstanding shares of its common
stock for the net settlement of SARs for payment of taxes related to such SARs, which were accounted for as a
share retirement.
NOTE 9 -
RELATED PARTY TRANSACTIONS
14
enhancement
of the Olaplex professional application, as well as other digital marketing services, all of which were
negotiated on an arm’s length basis and on market terms.
Tax
Receivable Agreement
In
connection with the Reorganization Transactions, the Company entered into the Tax Receivable Agreement with the
Pre-IPO Stockholders. See further discussion in “Note 2 – Summary of Significant Accounting Policies – Tax
Receivable Agreement”. During the three months ended September 30, 2023, the Company did not make a payment
to the Pre-IPO Stockholders. During the nine months ended September 30, 2023, the Company made a payment to
the Pre-IPO Stockholders of $16.6
million as required pursuant to the terms of the Tax Receivable Agreement. During the
three and nine months ended September 30, 2022, the Company made a payment to the Pre-IPO Stockholders of $
4.2
million as required pursuant to the terms of the Tax Receivable Agreement.
15
NOTE 10 - CONTINGENCIES
From
time to time, the Company is subject to various legal actions arising in the ordinary course of business. The
Company cannot predict with reasonable assurance the outcome of these legal actions brought against the Company
as they are subject to uncertainties. Accordingly, any settlement or resolution in these legal actions may occur
and affect the Company’s net income in such period as the settlement or resolution.
Pending Legal Proceedings:
On
November 17, 2022, a putative securities class action was filed against the Company and certain of its current
and former officers and directors in the United States District Court for the Central District of California,
captioned Lilien
v. Olaplex Holdings, Inc. et al.,
No. 2:22-cv-08395. A consolidated complaint was filed on April 28, 2023, which names as additional defendants
the underwriters for the Company’s IPO and various stockholders that sold shares of common stock of the Company
in the IPO. The action is brought on behalf of a putative class of purchasers of the Company’s common stock in
or traceable to the Company’s IPO and asserts claims under Sections 11, 12, and 15 of the Securities Act of
1933. The action seeks certification of the putative class, compensatory damages, attorneys’ fees and costs, and
any other relief that the court determines is appropriate. The defendants moved to dismiss the consolidated
complaint on July 19, 2023. The court held a hearing on the defendants’ motions to dismiss on October 16, 2023,
and a decision has yet to issue. The underwriter defendants have notified the Company of their intent to seek
indemnification from the Company pursuant to the IPO underwriting agreement regarding the claims asserted in
this action. The Company intends to vigorously defend the pending lawsuit.
On
February 9, 2023, twenty-eight
plaintiffs filed Albahae,
et al. v. Olaplex Holdings, Inc., et al.,
No. 2:23-cv-00982, a complaint alleging personal and economic injury and asserting claims for breach of
warranty, negligence/gross negligence, products liability, unjust enrichment, and violations of California False
Advertising Law and Unfair Competition Law, against the Company and Cosway Company, Inc., the Company’s primary
contract manufacturer, in the United States District Court for the Central District of California. On March 2,
2023, the plaintiffs amended the complaint to include seventy-three additional plaintiffs. The plaintiffs allege that certain
ingredients used in some Company products have purportedly caused irritation or posed a hazard to consumers, and
that the Company engaged in misrepresentation with respect to those products. The plaintiffs seek actual and
consequential damages, punitive damages, restitution in the form of disgorgement of profits, attorneys’ fees and
costs, and any other relief that the court determines is appropriate. On April 17, 2023, the Company moved to
dismiss and to sever the plaintiffs’ claims. On July 11, 2023, the Court granted the Company’s motion to sever
and dismissed all but the first named plaintiff. The Court also dismissed the operative complaint with leave to
re-file on the grounds that it now contained allegations that were not relevant to the claims of the one,
remaining plaintiff. On July 24, 2023, the remaining plaintiff filed a notice, voluntarily dismissing her claims
without prejudice.
Any
potential loss associated with these pending legal proceedings is not probable or reasonably estimable at this
time.
As
of September 30, 2023 and December 31, 2022, the Company was not subject to any other currently
pending legal matters or claims that could have a material adverse effect on its financial position, results of
operations, or cash flows should such litigation be resolved unfavorably.
16
NOTE 11 – NET INCOME PER SHARE
The
following is a reconciliation of the numerator and denominator in the basic and diluted net income per common
share computations:
Three
Months Ended
|
Nine Months Ended | ||||||||||||||||||||||
September
30, 2023 |
September
30, 2022 |
September
30, 2023 |
September
30, 2022 |
||||||||||||||||||||
Numerator: | |||||||||||||||||||||||
Net income | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Denominator: | |||||||||||||||||||||||
Weighted
average common shares outstanding – basic
|
|
|
|
|
|||||||||||||||||||
Dilutive common equivalent shares from equity options |
|
|
|
|
|||||||||||||||||||
Weighted
average common shares outstanding – diluted
|
|
|
|
|
|||||||||||||||||||
Net income per share: | |||||||||||||||||||||||
Basic | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Diluted | $ |
|
$ |
|
$ |
|
$ |
|
Options
to purchase 4,473,909 and 2,887,141 shares of the Company’s common
stock for the three and nine months ended September 30, 2023, respectively, and options to purchase
1,275,337 and 1,170,756 shares of the Company’s common
stock for the three and nine months ended September 30, 2022, respectively, were not included in the
computation of diluted net income per share because the exercise prices of these options were greater than the
average market price per share of the Company’s common stock for the applicable period, and therefore would have
been anti-dilutive.
17
ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim Condensed Consolidated Financial Statements and related notes included elsewhere in this Quarterly Report and with our audited Consolidated Financial Statements included in the 2022 Form 10-K.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim Condensed Consolidated Financial Statements and related notes included elsewhere in this Quarterly Report and with our audited Consolidated Financial Statements included in the 2022 Form 10-K.
Some
of the information contained in this discussion and analysis, including information with respect to our plans and
strategy for our business, includes forward-looking statements that involve risks and uncertainties. Our actual
results may differ materially from management’s expectations as a result of various factors. Factors that could
cause or contribute to these differences include, but are not limited to, those identified below and those
discussed in the section “Special Note Regarding Forward-Looking Statements” in this Quarterly Report and in “Item
1A. – Risk Factors” in the 2022 Form 10-K.
Company Overview
OLAPLEX
is an innovative, science-enabled, technology-driven beauty company. Since our inception in 2014, we have focused
on delivering effective, patent-protected and proven product performance in the prestige hair care category. Our
mission is to blaze new paths to well-being that ignite confidence from the inside out.
OLAPLEX
disrupted and revolutionized the prestige hair care category by creating the bond-building space in 2014. We have
grown from an initial assortment of three products sold exclusively through the professional channel to a broader
suite of products offered through the professional, specialty retail and DTC channels that have been developed to
address three key uses: treatment, maintenance and protection. Our patent-protected bond-building technology
relinks disulfide bonds in human hair that are destroyed via chemical, thermal, mechanical, environmental and
aging processes. Our current product portfolio comprises eighteen unique, complementary products specifically
developed to provide a holistic regimen for hair health.
The
strength of our business model and ability to scale have created a compelling financial profile historically
characterized by revenue growth and very strong profitability. We have developed a mutually reinforcing,
synergistic, omnichannel model that leverages the strength of each of our channels and our strong digital
capabilities that we apply across our sales platforms. Our professional channel serves as the foundation for our
brand. Through this channel, professional hairstylists introduce consumers to our products and, we believe,
influence consumer purchasing decisions. Our specialty retail channel works to increase awareness of, and
education for, our products and expand consumer penetration. Our DTC channel, comprised of Olaplex.com and sales
through third-party e-commerce platforms, also provides us with the opportunity to engage directly with our
consumers to provide powerful feedback that drives decisions we make around new product development.
Four Strategic Pillars
We
are focused on executing against four key strategic pillars that we believe will support our long-term growth.
These include igniting our global brand, disrupting with innovation, amplifying channel coverage and charting new
geographies. These key strategic pillars are supported by our efforts to build capabilities and infrastructure
that we believe will enable our aspirations.
Igniting our Global Brand
We
believe we have built one of the most powerful brands in the prestige hair care category. We plan to continue
growing awareness of our global brand, in an effort to deepen connections with existing customers as well as reach
new audiences. We will also continue to invest in enhancing our brand equity. Our marketing model remains focused
on implementing high return on investment, performance marketing activities aimed at fueling growth. Key levers of
our marketing include creative campaigns, organic social media activations, strategic paid media, education and
training regarding our brand, community engagement with our professional hairstylists, influencer partnerships,
and retailer activations such as sampling and in-store events.
Disrupting with Innovation
We
believe we have a strong pipeline of disruptive innovation that leverages our science-based technology and
patented Bis-amino ingredient. We plan to launch two-to-four products annually over the next five years. To
support this pipeline, we intend to continue to invest in research and development to strengthen our internal
innovation capabilities. We remain excited about the opportunity to enter additional hair care adjacent categories
and also other categories where our patents can serve as a foundation for entry that we believe is supported by
consumer trust in our brand.
18
Amplifying Channel Coverage
In
our professional channel, we have undertaken efforts to support strong relationships with the hairstylist
community and maintain brand awareness by increasing our field support efforts, deepening partnerships with
distributors and customers, and refreshing educational content. We are pursuing opportunities to further penetrate
premium and prestige salons. In specialty retail, we are enhancing visual merchandising in stores and deploying
targeted communications intended to enable new customer acquisition. For our DTC business, we are evolving the
digital experiences on Olaplex.com and third party e-commerce websites. On Olaplex.com, we expect to continue to
invest in site enhancements and more advanced personalization efforts.
Charting New Geographies
We
believe there is substantial opportunity to grow globally. Our priority international regions are currently key
markets in Europe and Asia. Across Europe and other regions, we aim to implement our business model by first
establishing a strong professional channel and then complementing that channel through entry into specialty retail
and DTC. In Asia, we intend to partner with distributors in the region that will support the omni-channel
distribution and sales for our brand.
Supporting our Four Strategic Pillars
To
enable these four key growth pillars, we intend to continue to build our capabilities and infrastructure. These
efforts extend across our organization, including focusing on cultivating top talent and building a strong
corporate culture, evolving our operational capabilities as we scale, and ensuring that we have financial
structure, technology and data to support our growth.
Business Environment & Trends
We
continue to monitor the effects of the global macroeconomic environment, including the risk of recession,
inflationary pressures, competitive products and discounting, currency volatility, rising interest rates, higher
costs of raw materials, social and political issues, geopolitical tensions and regulatory matters. We also are
mindful of inflationary pressures on our consumers, and are monitoring the impact that these inflationary
pressures may have on consumer spending and preferences and inventory rebalancing at our customers in an
increasingly competitive industry.
Competition
in the beauty industry is based on a variety of factors, including innovation, product efficacy, accessible
pricing, brand recognition and loyalty, service to the consumer, promotional activities, advertising, special
events, new product introductions, e-commerce initiatives and other activities. We have seen increased competitive
activity including discounting in the prestige hair care category, which may continue in a heightened inflationary
environment. We believe we have a well-recognized and strong reputation in our core markets and that the quality
and performance of our products, our emphasis on innovation, and our engagement with our professional and consumer
communities position us to compete effectively.
Overview of Third Quarter 2023 Financial Results
•Net
sales decreased 30.0% from $176.5 million in the three months ended September 30, 2022 to $123.6 million in
the three months ended September 30, 2023. For the three months ended September 30, 2023, net sales in
our professional channel decreased 23.3%, our specialty retail channel decreased 41.8% and our DTC channel
decreased 18.2%, in each case as compared to the three months ended September 30, 2022.
•Gross
profit margin decreased from 73.6% in the three months ended September 30, 2022 to 67.6% in the three months
ended September 30, 2023, primarily as a result of increased promotional allowance, an increased reserve for
product obsolescence, and higher input costs for raw materials.
•Operating
expenses for the three months ended September 30, 2023 increased by 13.8%, as compared to the three months
ended September 30, 2022, primarily as a result of increased investments in sales and marketing, higher
payroll due to workforce expansion, and higher employee benefit costs, partially offset by lower distribution and
fulfillment costs incurred in the three months ended September 30, 2023.
•Operating
income decreased from $88.7 million for the three months ended September 30, 2022 to $36.7 million for the
three months ended September 30, 2023.
•Net
income decreased from $60.8 million for the three months ended September 30, 2022 to $20.4 million for the
three months ended September 30, 2023.
19
Overview of Year to Date 2023 Financial Results
•Net
sales decreased 39.6% from $573.6 million in the nine months ended September 30, 2022 to $346.6 million in
the nine months ended September 30, 2023. For the nine months ended September 30, 2023, net sales in our
professional channel decreased 43.9%, our specialty retail channel decreased 46.8%, and our DTC channel decreased
19.3%, in each case as compared to the nine months ended September 30, 2022.
•Gross
profit margin decreased from 74.5% in the nine months ended September 30, 2022 to 69.8% in the nine months
ended September 30, 2023, primarily as a result of an increased reserve for product obsolescence, increased
promotional allowance, and higher input costs for raw materials and warehousing.
•Operating
expenses for the nine months ended September 30, 2023 increased by 36.9%, as compared to the nine months
ended September 30, 2022, primarily as a result of increased investments in sales and marketing, higher
professional fees, legal settlement costs, a one-time former distributor payment, payroll due to workforce
expansion, and employee benefit costs, partially offset by lower distribution and fulfillment costs incurred in
the nine months ended September 30, 2023.
•Operating
income decreased from $317.3 million for the nine months ended September 30, 2022 to $91.1 million for the
nine months ended September 30, 2023.
•Net
income decreased from $210.4 million for the nine months ended September 30, 2022 to $47.5 million for the
nine months ended September 30, 2023.
Results of operations
Comparison of the Three Months Ended September 30, 2023 to the Three Months
Ended September 30, 2022
The
following table sets forth our Condensed Consolidated Statements of Operations and Comprehensive Income data for
each of the periods presented:
Three Months Ended September 30, | |||||||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||
(in thousands) | % of Net sales | (in thousands) | % of Net sales | ||||||||||||||||||||
Net sales | $ | 123,555 | 100.0 | % | $ | 176,454 | 100.0 | % | |||||||||||||||
Cost of sales: | |||||||||||||||||||||||
Cost of product (excluding amortization) | 37,415 | 30.3 | 45,484 | 25.8 | |||||||||||||||||||
Amortization of patented formulations | 2,592 | 2.1 | 1,142 | 0.6 | |||||||||||||||||||
Total cost of sales | 40,007 | 32.4 | 46,626 | 26.4 | |||||||||||||||||||
Gross profit | 83,548 | 67.6 | 129,828 | 73.6 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Selling, general, and administrative | 36,433 | 29.5 | 30,807 | 17.5 | |||||||||||||||||||
Amortization of other intangible assets | 10,378 | 8.4 | 10,329 | 5.9 | |||||||||||||||||||
Total operating expenses | 46,811 | 37.9 | 41,136 | 23.3 | |||||||||||||||||||
Operating income | 36,737 | 29.7 | 88,692 | 50.3 | |||||||||||||||||||
Interest expense, net | (9,510) | (7.7) | (10,499) | (5.9) | |||||||||||||||||||
Other expense, net | (970) | (0.8) | (2,251) | (1.3) | |||||||||||||||||||
Income
before provision for income taxes
|
26,257 | 21.3 | 75,942 | 43.0 | |||||||||||||||||||
Income tax provision | 5,891 | 4.8 | 15,179 | 8.6 | |||||||||||||||||||
Net income | $ | 20,366 | 16.5 | $ | 60,763 | 34.4 | |||||||||||||||||
Net
Sales
We
distribute products in the U.S. and internationally through professional distributors in the salon channel,
directly to retailers for sale in their physical stores and e-commerce sites, and DTC through sales to third party
e-commerce customers and through our Olaplex.com websites. As such, our three business channels consist of
professional, specialty retail and
20
DTC
as follows:
(in thousands) |
For
the Three Months Ended September 30,
|
||||||||||||||||||||||
2023 | 2022 |
$
Change
|
%
Change
|
||||||||||||||||||||
Net sales by Channel: | |||||||||||||||||||||||
Professional | $ | 48,289 | $ | 62,991 | $ | (14,702) | (23.3) | % | |||||||||||||||
Specialty retail | 43,159 | 74,191 | (31,032) | (41.8) | % | ||||||||||||||||||
DTC | 32,107 | 39,272 | (7,165) | (18.2) | % | ||||||||||||||||||
Total Net sales | $ | 123,555 | $ | 176,454 | $ | (52,899) | (30.0) | % |
Total
net sales declined 30.0% in the three months ended September 30, 2023 compared to the same period in 2022,
primarily attributed to a lower level of demand. These impacts were partially offset by our launches of No. 5P
Blonde Enhancer™ Toning Conditioner, Olaplex®
Volumizing Blow Dry Mist, LASHBOND®
Serum, which is our first hair care adjacent product, and No. 4D Clean Volume Detox Dry Shampoo, as well as the
impact of new customers within each channel. Net sales declined primarily in the United States, Canada, the United
Kingdom and Australia, partially offset by increases in South East Asia, the Middle East and Latin America.
Cost
of Sales and Gross Profit
(in thousands) |
For
the Three Months Ended September 30,
|
|
$ Change | % Change | |||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||
Cost of sales | $ | 40,007 | $ | 46,626 |
|
$ | (6,619) |
|
(14.2) | % | |||||||||||||
Gross profit | $ | 83,548 | $ | 129,828 |
|
$ | (46,280) |
|
(35.6) | % |
Our
cost of sales decreased primarily due to declining product sales in the three months ended September 30,
2023. The Company also recorded write-off and disposal expenses of $1.6 million for the same period in 2022 as a
result of regulation changes in the European Union. These decreases were partially offset by a $3.6 million
inventory obsolescence reserve recorded during the three months ended September 30, 2023, and increases in
cost of sales resulting from inflationary pressures.
As
a result of the activity described above regarding Net sales and Cost of sales, our gross profit margin decreased
from 73.6% in the three months ended September 30, 2022 to 67.6% in the three months ended September 30,
2023.
Operating
Expenses
(in thousands) |
For
the Three Months Ended September 30,
|
|
|||||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Selling, general, and administrative expenses | $ | 36,433 | $ | 30,807 |
|
$ | 5,626 |
|
18.3 | % | |||||||||||||
Amortization of other intangible assets | 10,378 | 10,329 |
|
49 |
|
0.5 | % | ||||||||||||||||
Total operating expenses | $ | 46,811 |
|
$ | 41,136 |
|
$ | 5,675 | 13.8 | % |
The
increase in selling, general and administrative expenses was primarily driven by an increase of $3.4 million
in investments in sales and marketing, $2.9 million in payroll expenses driven by workforce expansion, and
$0.7 million of employee benefit costs, partially offset by a $0.8 million decrease in distribution and
fulfillment costs related to the decrease in product sales volume during the three months ended September 30,
2023.
21
Interest
Expense, Net
(in thousands) |
For
the Three Months Ended September 30,
|
|
|
|
|||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Interest expense | $ | (14,692) | $ | (11,142) | $ | (3,550) |
|
31.9 | % | ||||||||||||||
Interest income | 5,182 | $ | 643 | $ | 4,539 |
|
* | ||||||||||||||||
Interest expense, net | $ | (9,510) | $ | (10,499) | $ | 989 |
|
(9.4) | % |
*Percent
change not meaningful
Interest
expense, net decreased due to a receipt of funds resulting from settlements of the Company's interest rate cap,
partially offset by increased interest rates in response to the inflationary environment during the three months
ended September 30, 2023. See “Liquidity and Capital Resources Requirements – Credit Facility” for additional
information regarding our outstanding debt.
We
also benefited during the three months ended September 30, 2023 from $5.2 million of interest income
from highly liquid investments with a maturity of three months or less.
Other
Expense, Net
(in thousands) |
For
the Three Months Ended September 30,
|
|
|
|
|||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Other expense, net | $ | (970) | $ | (2,251) |
|
$ | 1,281 | (56.9) | % |
Other
expense, net decreased primarily due to lower foreign currency transaction losses driven by the performance of the
U.S. dollar.
Income
Tax Provision
(in thousands) |
For
the Three Months Ended September 30,
|
|
|
|
|||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Income tax provision | $ | 5,891 | $ | 15,179 | $ | (9,288) | (61.2) | % |
Our
effective tax rate was 22.4% for the three months ended September 30, 2023, as compared to 20.0% for the
three months ended September 30, 2022. Our effective tax rate for the three months ended September 30,
2023 is higher than the statutory rate of 21% primarily due to the effect of state income taxes, partially offset
by the foreign derived intangible income deduction ("FDII"), which results in income from the Company’s sales to
foreign customers being taxed at a lower effective tax rate. Our effective tax rate in the three months ended
September 30, 2022 was lower than the statutory tax rate of 21% primarily due to the benefit associated with
the FDII, partially offset by the net impact of state income taxes. The increase in the effective tax rate from
the comparative prior three months period is primarily due to the impact in the quarter of updating to the annual
effective tax rate.
22
Comparison of the Nine Months Ended September 30, 2023 to the Nine Months Ended
September 30, 2022
The
following table sets forth our Condensed Consolidated Statements of Operations and Comprehensive Income data for
each of the periods presented:
Nine Months Ended September 30, | |||||||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||
(in thousands) | % of Net sales | (in thousands) | % of Net sales | ||||||||||||||||||||
Net sales | $ | 346,583 | 100.0 | % | $ | 573,553 | 100.0 | % | |||||||||||||||
Cost of sales: | |||||||||||||||||||||||
Cost of product (excluding amortization) | 98,431 | 28.4 | 140,999 | 24.6 | |||||||||||||||||||
Amortization of patented formulations | 6,298 | 1.8 | 5,091 | 0.9 | |||||||||||||||||||
Total cost of sales | 104,729 | 30.2 | 146,090 | 25.5 | |||||||||||||||||||
Gross profit | 241,854 | 69.8 | 427,463 | 74.5 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Selling, general, and administrative | 119,770 | 34.6 | 79,232 | 13.8 | |||||||||||||||||||
Amortization of other intangible assets | 31,025 | 9.0 | 30,890 | 5.4 | |||||||||||||||||||
Total operating expenses | 150,795 | 43.5 | 110,122 | 19.2 | |||||||||||||||||||
Operating income | 91,059 | 26.3 | 317,341 | 55.3 | |||||||||||||||||||
Interest expense, net | (30,259) | (8.7) | (30,653) | (5.3) | |||||||||||||||||||
Other expense, net | |||||||||||||||||||||||
Loss on extinguishment of debt | — | — | (18,803) | (3.3) | |||||||||||||||||||
Other expense, net | (1,328) | (0.4) | (3,852) | (0.7) | |||||||||||||||||||
Total other expense, net | (1,328) | (0.4) | (22,655) | (3.9) | |||||||||||||||||||
Income
before provision for income taxes
|
59,472 | 17.2 | 264,033 | 46.0 | |||||||||||||||||||
Income tax provision | 11,986 | 3.5 | 53,594 | 9.3 | |||||||||||||||||||
Net income | $ | 47,486 | 13.7 | $ | 210,439 | 36.7 | |||||||||||||||||
Net
Sales
Net
sales by channel for the nine months ended September 30, 2023 and September 30, 2022 were as
follows:
(in thousands) |
For
the Nine Months Ended September 30,
|
||||||||||||||||||||||
2023 | 2022 |
$
Change
|
%
Change
|
||||||||||||||||||||
Net sales by Channel: | |||||||||||||||||||||||
Professional | $ | 137,626 | $ | 245,539 | $ | (107,913) | (43.9) | % | |||||||||||||||
Specialty retail | 107,785 | 202,692 | (94,907) | (46.8) | % | ||||||||||||||||||
DTC | 101,172 | 125,322 | (24,150) | (19.3) | % | ||||||||||||||||||
Total net sales | $ | 346,583 | $ | 573,553 | $ | (226,970) | (39.6) | % |
Total
net sales declined 39.6% in the nine months ended September 30, 2023 compared to the same period in 2022,
primarily attributed to a lower level of demand and inventory rebalancing, particularly within the Professional
and Specialty Retail channels. The Company was also lapping $22.0 million of new product offering and $10 million
of inventory pipeline to a key specialty retailer in the same period in 2022. These impacts were partially offset
by our launches of LASHBOND®
Serum, which is our first hair care adjacent product, No. 4D Clean Volume Detox Dry Shampoo, Olaplex®Volumizing
Blow Dry Mist, and No. 5P Blonde Enhancer™ Toning Conditioner, as well as the impact of new customers within each
channel. Net sales declined primarily in the United States, Canada and the United Kingdom, partially offset by
increases in Southeast Asia and the Middle East.
Cost
of Sales and Gross Profit
(in thousands) |
For
the Nine Months Ended September 30,
|
|
$ Change | % Change | |||||||||||||||||||
2023 | 2022 | ||||||||||||||||||||||
Cost of sales | $ | 104,729 | $ | 146,090 |
|
$ | (41,361) |
|
(28.3) | % | |||||||||||||
Gross profit | $ | 241,854 | $ | 427,463 |
|
$ | (185,609) |
|
(43.4) | % |
23
Our
cost of sales decreased primarily due to declining product sales in the nine months ended September 30, 2023.
The Company also recorded write-off and disposal expenses of $4.3 million and $1.6 million for the same period in
2022 as a result of regulation changes in the European Union. These decreases were partially offset by a $9.8
million reserve for product obsolescence recorded during the nine months ended September 30, 2023, and
increases in cost of sales resulting from inflationary pressures.
As
a result of the activity described above regarding Net sales and Cost of sales, our gross profit margin decreased
from 74.5% in the nine months ended September 30, 2022 to 69.8% in the nine months ended September 30,
2023.
Operating
Expenses
(in thousands) | For the Nine Months Ended September 30, |
|
|||||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Selling, general, and administrative expenses | $ | 119,770 | $ | 79,232 |
|
$ | 40,538 |
|
51.2 | % | |||||||||||||
Amortization of other intangible assets | 31,025 | 30,890 |
|
135 |
|
0.4 | % | ||||||||||||||||
Total operating expenses | $ | 150,795 |
|
$ | 110,122 |
|
$ | 40,673 | 36.9 | % |
Selling,
general and administrative expenses increased primarily due to an increase of $26.2 million in investments in
sales and marketing, payroll expenses of $8.0 million driven by workforce expansion, $6.5 million
related to the combination of a one-time former distributor payment, professional expenses, and legal settlement
costs, and increased employee benefit costs of $2.9 million, partially offset by a $3.5 million decrease
in distribution and fulfillment costs related to the decrease in product sales volume during the nine months ended
September 30, 2023.
Interest
Expense, Net
(in thousands) |
For
the Nine Months Ended September 30,
|
|
|
|
|||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Interest expense | $ | (43,283) | $ | (31,296) | $ | (11,987) |
|
38.3 | % | ||||||||||||||
Interest income | 13,024 | 643 | 12,381 |
|
* | ||||||||||||||||||
Interest expense, net | $ | (30,259) | $ | (30,653) | $ | 394 |
|
(1.3) | % |
*Percent
change not meaningful.
Interest
expense, net remained flat during the nine months ended September 30, 2023. See “Liquidity and Capital
Resources Requirements – Credit Facility” for additional information on our outstanding debt.
We
also benefited during the nine months ended September 30, 2023 from $13.0 million of interest income
from highly liquid investments with a maturity of three months or less.
Other
(Expense), Net
(in thousands) |
For
the Nine Months Ended September 30,
|
|
|
|
|||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Loss on extinguishment of debt | $ | — | $ | (18,803) | $ | 18,803 | — | % | |||||||||||||||
Other expense, net | (1,328) | $ | (3,852) | $ | 2,524 | (65.5) | % | ||||||||||||||||
Total other expense, net | $ | (1,328) | $ | (22,655) |
|
$ | 21,327 | (94.1) | % |
As
a result of the refinancing of the 2020 Credit Agreement that occurred during the nine months ended
September 30, 2022, we recorded an $18.8 million loss on extinguishment of debt in that period. Other
expense, net decreased in the nine months ended September 30, 2023 primarily due to a decrease in foreign
currency transaction losses driven by the performance of the U.S. dollar.
Income
Tax Provision
24
(in thousands) |
For
the Nine Months Ended September 30,
|
|
|
|
|||||||||||||||||||
2023 | 2022 |
|
$
Change
|
%
Change
|
|||||||||||||||||||
Income tax provision | $ | 11,986 | $ | 53,594 | $ | (41,608) | (77.6) | % |
Our
effective tax rate was 20.2% for the nine months ended September 30, 2023, as compared to 20.3% for the nine
months ended September 30, 2022. Our effective tax rates for the nine months ended September 30, 2023
and 2022 are lower than the statutory tax rate of 21% primarily due to the benefit associated with the FDII,
partially offset by the net impact of state income taxes.
Tax
Receivable Agreement
The
Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that the Company and
its subsidiaries will earn sufficient taxable income to realize the full tax benefits subject to the Tax
Receivable Agreement. Updates to the blended state tax rate and allocation of U.S. versus foreign sourced income
may impact the established liability and changes would be recorded to other income (expense) in the period we made
the determination. We expect that future payments under the Tax Receivable Agreement relating to the Pre-IPO Tax
Assets could aggregate to $205.6 million over the 13-year remaining period under the Tax Receivable Agreement.
Payments under the Tax Receivable Agreement, which began in the year ended December 31, 2022, are not conditioned
upon the parties’ continued ownership of equity in the Company. During the nine months ended September 30,
2023, the Company made a payment to the Pre-IPO Stockholders of $16.6 million as required pursuant to the
terms of the Tax Receivable Agreement. During the three and nine months ended September 30, 2022, the Company
made a payment to the Pre-IPO Stockholders of $4.2 million as required pursuant to the terms of the Tax
Receivable Agreement. The remaining Tax Receivable Agreement payment obligation as of September 30, 2023 is
$205.6 million, of which $189.4 million was recorded in long term liabilities and $16.2 million was recorded in
current liabilities.
Financial Condition, Liquidity and Capital Resources
Overview
Our
primary recurring source of cash is the collection of proceeds from the sale of our products to our customers,
including cash periodically collected in advance of delivery or performance.
Our
primary use of cash is for working capital and payment of our operating costs, which consist primarily of
employee-related expenses as well as general operating expenses for marketing, fulfillment costs of customer
orders, overhead costs, innovation, capital expenditures and debt servicing. We also utilize cash for strategic
investments. Fluctuations in working capital are primarily caused by customer demand of our product, timing of
when a retailer rearranges or restocks our products, timing of inventory purchases, and timing of our payables and
expenses. Capital expenditures typically vary and are currently limited, and future capital expenditure
requirements depend on strategic initiatives selected for the fiscal year, including investments in
infrastructure, expansion into new national and international distributors and expansion of our customer
base.
A
considerable portion of our operating income is related to sales to customers outside of the U.S.; however, the
majority of our bank deposits are held within the U.S.
As
of September 30, 2023, we had $429.6 million of cash and cash equivalents. In addition, as of
September 30, 2023, we had borrowing capacity of $150.0 million under the 2022 Revolver, plus $114.8 million
of working capital excluding cash and cash equivalents for a combined liquidity position of
$694.4
million.
25
Cash Flows
The
following table summarizes our cash flows for the periods presented:
For the Nine Months Ended September 30,
|
|||||||||||
(in thousands) | 2023 | 2022 | |||||||||
Net cash provided by (used in): | |||||||||||
Operating activities | $ | 128,497 | $ | 181,807 | |||||||
Investing activities | (2,902) | (1,712) | |||||||||
Financing activities | (18,817) | (117,084) | |||||||||
Net increase in cash and cash equivalents: | $ | 106,778 | $ | 63,011 |
Operating Activities
The
decrease in net cash provided by operating activities during the nine months ended September 30,
2023 compared to the same period in 2022
was primarily a result of a decrease in net income of $163.0 million, changes in working capital and adjusting
items to Operating Cash Flows to reconcile to Net income from operations, and increases in inventory obsolescence,
write-offs and disposal adjustments of $3.8 million, partially offset by the loss on extinguishment of debt of
$18.8 million related to the refinancing of the 2020 Credit Agreement recorded in the nine months ended
September 30, 2022.
Investing Activities
Our
investing activities included purchases of product technologies, software, property and equipment during the nine
months ended September 30,
2023 and 2022.
Financing Activities
Our
financing activities for the nine months ended September 30,
2023 primarily consisted of cash outflows for payments on our long-term debt and debt issuance costs, payments to
our pre-IPO stockholders pursuant to our Tax Receivable Agreement, and payments for shares withheld and retired
for taxes and exercise price for SARs, partially offset by cash received by the Company from stock option
exercises.
For the nine months ended September 30, 2022, our financing activities primarily consisted of cash outflows
for payments on our long-term debt and debt issuance costs, and
payments for shares withheld and retired for taxes and exercise price for SARs, offset by proceeds from the
issuance of the 2022 Credit Agreement.
Liquidity and Capital Resources Requirements
Based
on past performance and current expectations, we believe that our cash, cash equivalents and cash generated from
operations will be sufficient to meet anticipated operating costs, required payments of principal and interest,
working capital needs, ordinary course capital expenditures, and other commitments for at least the next 12
months.
If
necessary, we may borrow funds under our 2022 Revolver to finance our liquidity requirements, subject to customary
borrowing conditions. To the extent additional funds are necessary to meet our long-term liquidity needs as we
continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of
additional indebtedness, equity financings or a combination of these potential sources of funds; however, such
financing may not be available on favorable terms, or at all. Our ability to meet our operating, investing and
financing needs depends, to a significant extent, on our future financial performance, which will be subject in
part to general economic, competitive, financial, regulatory and other factors that are beyond our control,
including those described elsewhere in “Risk Factors” in our 2022 Form 10-K. In addition to these general economic
and industry factors, the principal factors in determining whether our cash flows will be sufficient to meet our
liquidity requirements will be our ability to continue providing innovative products to our customers and
consumers and manage production and our supply chain.
2022 Credit Facility
As
of September 30, 2023, we had outstanding indebtedness under the 2022 Credit Agreement of $664.9 million, of
which $6.8 million was classified as current. As of September 30, 2023, we had $150.0 million of available
borrowing capacity under the 2022 Revolver.
The
interest rate on outstanding amounts under the 2022 Term Loan Facility was 8.9% per annum as of September 30,
2023.
We have not drawn on the 2022 Revolver as of September 30,
2023.
The 2022 Term Loan Facility is repayable in mandatory quarterly installments equal to $1.7 million, with the
balance payable at maturity.
26
The
2022 Credit Agreement includes, among other things, customary negative and affirmative covenants (including
reporting, financial, and maintenance covenants) and events of default (including a change of control) for
facilities of this type. In addition, the 2022 Credit Agreement includes a springing first lien leverage ratio
financial covenant, which is applicable only to the lenders under the 2022 Revolver. We were in compliance with
our financial covenants on September 30, 2023 and December 31, 2022. The 2022 Term Loan Facility and the
2022 Revolver are secured by substantially all of the assets of Olaplex, Inc. and the other guarantors, subject to
certain exceptions and thresholds.
On
August 11, 2022, we entered into an interest rate cap transaction in connection with the 2022 Term Loan Facility,
with a notional amount of $400.0 million, in order to limit its exposure to potential increases in future
interest rates related to the 2022 Term Loan Facility. We have designated the interest rate cap as a cash-flow
hedge for accounting purposes.
See
“Note 7
Long-Term
Debt” in the Notes to the Condensed Consolidated Financial Statements included in Item 1. Financial Statements of
this Quarterly Report for additional information on our indebtedness and interest rate cap.
Tax Receivable Agreement Obligations
As
part of the IPO, we entered into the Tax Receivable Agreement under which we will be required to pay to the
Pre-IPO Stockholders 85% of the federal, state or local tax cash savings that we actually realize on our taxable
income following the IPO, as a result of the amortization of intangible assets and capitalized transaction costs
that existed as of the transaction date. Under the Tax Receivable Agreement, generally we will retain the benefit
of the remaining 15% of the applicable tax savings.
The
Tax Receivable Agreement liability is calculated based on current tax laws and the assumption that the Company and
its subsidiaries will earn sufficient taxable income to realize the full tax benefits subject to the Tax
Receivable Agreement. Updates to our blended state tax rate and allocation of U.S. versus foreign sourced income
may impact the established liability and changes would be recorded to other income (expense) in the period we made
the determination. We expect that future payments under the Tax Receivable Agreement relating to the Pre-IPO Tax
Assets could aggregate to $205.6 million over the 13-year remaining period under the Tax Receivable Agreement.
Payments under the Tax Receivable Agreement, which began in year ended December 31, 2022, are not conditioned upon
the parties’ continued ownership of equity in the Company.
Contractual Obligations and Commitments
There
were no material changes to our contractual obligations since the filing of our 2022 Form 10-K.
Critical Accounting Policies and Estimates
Our
unaudited interim Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP,
which requires us to make estimates and assumptions that affect reported amounts. The estimates and assumptions
are based on historical experience and on other factors that we believe to be reasonable. Actual results may
differ from those estimates. We review these estimates on a periodic basis to ensure reasonableness. Although
actual amounts may differ from such estimated amounts, we believe such differences are not likely to be material.
For additional detail regarding our critical accounting policies including revenue recognition, inventory, and the
Tax Receivable Agreement, see our discussion for the year ended December 31, 2022 in
the 2022 Form 10-K.
There have been no material changes to these policies in the nine months ended September 30, 2023.
27
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We
are exposed to certain market risks arising from transactions in the normal course of our business. This includes
risk associated with interest rates, inflation and foreign exchange.
Interest Rate Risk
Our
results are subject to risk from interest rate fluctuations on borrowings under the 2022 Credit Agreement. Our
borrowings bear interest at a variable rate; therefore, we are exposed to market risks relating to changes in
interest rates. When the reference rates under our 2022 Term Loan Facility increase, the interest payments we must
make thereon also increase, which can impact our future earnings and cash flows. As of
September 30, 2023,
we had
$664.9 million of outstanding variable rate loans under the 2022 Term Loan Facility. Based on our
September 30, 2023 variable rate loan balances, an increase or decrease of 1% in the effective interest rate
would cause an increase or decrease in interest cost of approximately $6.6 million over the next 12 months.
Interest Rate Cap
On
August 11, 2022, we entered into an interest rate cap transaction (the “interest rate cap”) in connection with the
2022 Term Loan Facility, as more fully described in “Note 7 Long-Term Debt” in the Notes to the Condensed
Consolidated Financial Statements included in Item 1. Financial Statements of this Quarterly Report. We use the
interest rate cap to add stability to interest expense and to manage our exposure to interest rate movements. The
fair value of the interest rate cap is measured at the end of each reporting period using observable inputs other
than quoted prices. The fair value of the interest rate cap recorded in other assets at September 30, 2023
was $4.5 million. A hypothetical 50 basis point increase in interest rates would result in an increase to the fair
value of the interest rate cap of approximately $1.1 million. A hypothetical 50 basis point decrease in
interest rates would result in a decrease to the fair value of the interest rate cap of approximately
$1.0 million.
Inflation
Inflationary
factors such as increases in the cost to produce our products and overhead costs have adversely affected, and may
continue to adversely affect, our operating results. During the three and nine months ended September 30,
2023, our gross profit margin was negatively impacted by increased input costs for raw materials. Sustained
increases in warehousing costs, transportation costs, wages and raw material costs, or other inflationary
pressures in the future, may have an adverse effect on our ability to maintain current levels of gross profit
margin if the selling prices of our products do not increase with these increased costs, or if we cannot identify
other cost efficiencies.
Foreign Exchange Risk
Our
reporting currency, including our U.K. foreign subsidiary, Olaplex UK Limited, is the U.S. dollar. Gains or losses
due to transactions in foreign currencies are reflected in the Consolidated Statements of Operations and
Comprehensive Income under the line-item Other (expense) income, net. We have not engaged in the hedging of
foreign currency transactions to date, although we may choose to do so in the future. We do not believe that an
immediate 10% increase or decrease in the relative value of the U.S. dollar to other currencies would have a
material effect on our consolidated financial statements.
28
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are
designed to ensure that information required to be disclosed in the reports that we file or submit under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported
within the time periods specified in the SEC’s rules and forms and to ensure that information required to be
disclosed is accumulated and communicated to our management, including our interim Chief Executive Officer and
Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Our
management has evaluated, under the supervision and with the participation of our interim Chief Executive Officer
and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report.
Based on that evaluation, our interim Chief Executive Officer and Chief Financial Officer have concluded that our
disclosure controls and procedures were effective as of September 30, 2023.
Changes in Internal Control Over Financial Reporting
There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of
the Exchange Act) that occurred during the quarter ended September 30, 2023 that have materially affected, or
are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations in Effectiveness of Controls
Our
management, including our interim Chief Executive Officer and Chief Financial Officer, does not expect that our
disclosure controls and procedures or our internal control over financial reporting will prevent or detect all
errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met. Further, the design of a control system
must reflect the fact that there are resource constraints, and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can
provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been
detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and
that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people or by management override of the controls. The
design of any system of controls is also based in part upon certain assumptions about the likelihood of future
events, and there can be no assurance that any design will succeed in achieving its stated goals under all
potential future conditions; over time, controls may become inadequate because of changes in conditions, or the
degree of compliance with policies or procedures may deteriorate. Due to the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and not be detected.
29
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We
have, and may in the future, from time to time, become involved in litigation or other legal proceedings
incidental to our business, including litigation related to intellectual property, regulatory matters, contract,
advertising and other consumer claims. In the opinion of our management, reasonably possible losses in addition to
the amounts accrued for any such litigation and legal proceedings are not material to our consolidated financial
statements. In addition, we believe that protecting our intellectual property is essential to our business and we
have in the past, and may in the future, become involved in proceedings to enforce our rights. Regardless of
outcome, litigation (including the litigation referenced below) can have an adverse impact on our reputation,
financial condition and business, including by utilizing our resources and potentially diverting the attention of
our management from the operation of our business.
For
detail on certain legal proceedings, see “Note 10 Contingencies - Pending Legal Proceedings” included in the Notes
to the Condensed Consolidated Financial Statements included in Part I, Item 1. Financial Statements of this
Quarterly Report.
ITEM 1A. RISK FACTORS
An
investment in our common stock involves risks. For a detailed discussion of the risks that affect our business
please refer to “Item 1A. – Risk Factors" in the 2022 Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not
applicable.
ITEM 5. OTHER INFORMATION
(c)
During the three months ended September 30, 2023, no director or “officer” (as defined in Rule 16a-1(f) under the
Exchange Act) of the Company
adopted
or
terminated
a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is
defined in Item 408(a) of Regulation S-K.
30
ITEM 6. EXHIBITS
Exhibit Number | Description | |||||||
32.1†
|
||||||||
32.2†
|
||||||||
101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | |||||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
#
Indicates a management contract or compensation plan, contract or arrangement.
†
This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject
to the liability of that section. Such certification will not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically
incorporated by reference into such filing.
31
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.
OLAPLEX HOLDINGS, INC. | |||||||||||
By: | /s/ John P. Bilbrey | ||||||||||
November 7, 2023 | Name: | John P. Bilbrey | |||||||||
Title: | Interim Chief Executive Officer | ||||||||||
(Principal Executive Officer) | |||||||||||
By: | /s/ Eric Tiziani | ||||||||||
November 7, 2023 | Name: | Eric Tiziani | |||||||||
Title: | Chief Financial Officer | ||||||||||
(Principal
Financial Officer)
|
32